| Identification | Back Directory | [Name]
1-(3,4-dihydroxyphenyl)-2-[1-(4-methylphenyl)tetrazol-5-yl]sulfanylethanone | [CAS]
634169-12-3 | [Synonyms]
1-(3,4-dihydroxyphenyl)-2-[1-(4-methylphenyl)tetrazol-5-yl]sulfanylethanone
Ethanone, 1-(3,4-dihydroxyphenyl)-2-[[1-(4-methylphenyl)-1H-tetrazol-5-yl]thio]-
1-(3,4-dihydroxyphenyl)-2-{[1-(4-methylphenyl)-1H -1,2,3,4-tetrazol-5-yl]sulfanyl}ethan-1-one | [Molecular Formula]
C16H14N4O3S | [MDL Number]
MFCD03820078 | [MOL File]
634169-12-3.mol | [Molecular Weight]
342.37 |
| Chemical Properties | Back Directory | [Boiling point ]
649.7±65.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
7.48±0.20(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Biological Activity]
SNI-1 is an inhibitor of CARP-1(CCAR1)-NEMO (NF-KB essential modulator) interaction th at binds to CARP-1. SNI-1 inhibits chemotherapy-dependent canonical NF-KB signaling and attenuates secretion of the pro-inflammatory cytokines TNFαIL-1βand IL-8. It potentiates chemotherapeutic effects of DNA damaging agents such as Cisplatin and Adriamycin (doxorubicin) in several cancer cell lines including human triple-negative breast cancer (TNBC). |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|